Aldevron pursues city approval for Minnesota expansion

Last June, Finance & Commerce said Aldevron had paid $27 million in cash to buy the building located at 7075 Flying Cloud Drive. This week, Eden Prairie Local News reported the firm is now seeking permission to add a two-story, 96,244 square-foot expansion to its existing building.

While no specifics about the expansion were divulged, contract development manufacturing organization (CDMO) Aldevron (acquired by Danaher Corporation in June 2021 for $9.6 billion) told BioProcess Insider “we are currently in the detailed design phase and are enthusiastic to showcase our plans to meet the growing global demand for DNA, RNA, and proteins.”

“As one of the world’s largest custom manufacturers of these biologics, this project allows Aldevron to continue to support our clients, the patients they serve, and the delivery of therapeutic solutions to aid biopharma innovators in making progress toward a world by reducing or eliminating disease. We are greatly looking forward to working with the City of Eden Prairie and its community leaders throughout this process.”

In May, the firm upped its lipid nanoparticle (LNP) encapsulation and aseptic fill/finish capabilities in Fargo, North Dakota due to post-COVID demand for messenger RNA (mRNA) therapies and vaccines.

Furthermore, in August 2021 Ginkgo Bioworks said its partnership with Aldevron had led to an mRNA breakthrough with their manufacturing approach proving 10 times more efficient than the previous process. Under the terms of the partnership, Aldevron has the exclusive rights to the recently developed production process.